03/16/23 3:01 AMNasdaq : OKYO clinical triallow floatOKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public WebsiteOKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, todayRHEA-AIneutral
03/14/23 3:00 AMNasdaq : OKYO low floatOKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior managementNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT ISRHEA-AIneutral
03/13/23 4:15 PMNasdaq : OKYO low floatOKYO Pharma Limited Prices $5.3 Million Offering of ADSsOKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, announced the pricing of aRHEA-AIneutral
02/28/23 2:00 AMNasdaq : OKYO clinical triallow floatOKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye DiseaseOKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, todayRHEA-AIneutral
02/23/23 2:00 AMNasdaq : OKYO managementlow floatOKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory BoardOKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceuticalRHEA-AIneutral
02/21/23 7:00 AMNasdaq : OKYO conferenceslow floatOKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in thisRHEA-AIneutral
12/30/22 2:00 AMNasdaq : OKYO low floatOKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces itsRHEA-AIneutral
12/22/22 2:00 AMNasdaq : OKYO low floatOKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye DiseaseOKYO PharmaRHEA-AIneutral
12/21/22 2:00 AMNasdaq : OKYO conferenceslow floatOKYO to Participate at Biotech ShowcaseOKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market,RHEA-AIneutral
12/06/22 2:00 AMNasdaq : OKYO low floatOKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SECOKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, thatRHEA-AIneutral